Literature DB >> 23254152

Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa.

James C M Brust1, N Sarita Shah, Theo L van der Merwe, Sheila Bamber, Yuming Ning, Moonseong Heo, Anthony P Moll, Marian Loveday, Umesh G Lalloo, Gerald H Friedland, Neel R Gandhi.   

Abstract

Most patients with multidrug-resistant tuberculosis (MDR-TB) in South Africa are HIV-infected, but the safety and tolerability of cotreatment are unknown. The authors reviewed all adverse events (AEs) for patients with MDR-TB in a home-based treatment program in rural KwaZulu-Natal. Of 91 MDR-TB patients, 74 (81%) were HIV-positive and receiving antiretroviral therapy. AEs were common, but most were mild and did not require therapy modification. The most common severe AEs were hypothyroidism (36%) and psychosis (5%). Patients receiving concurrent antiretroviral therapy did not experience AEs more frequently than those on MDR-TB therapy alone. Concurrent treatment for MDR-TB/HIV can be safely administered in a home-based care setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23254152      PMCID: PMC3641171          DOI: 10.1097/QAI.0b013e31828175ed

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  19 in total

1.  Psychiatric and neurological reactions to cycloserine in the treatment of tuberculosis.

Authors:  W C LEWIS; G CALDEN; J R THURSTON; W E GILSON
Journal:  Dis Chest       Date:  1957-08

2.  Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.

Authors:  S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; A Yedilbayev; M L Rich; J S Mukherjee; J J Furin; S Atwood; P E Farmer; S Keshavjee
Journal:  Int J Tuberc Lung Dis       Date:  2007-12       Impact factor: 2.373

3.  Side effects associated with the treatment of multidrug-resistant tuberculosis.

Authors:  T Törün; G Güngör; I Ozmen; Y Bölükbaşi; E Maden; B Biçakçi; G Ataç; T Sevim; K Tahaoğlu
Journal:  Int J Tuberc Lung Dis       Date:  2005-12       Impact factor: 2.373

4.  Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran.

Authors:  Parvaneh Baghaei; Payam Tabarsi; Donna Dorriz; Majid Marjani; Masoud Shamaei; Majid Valiollah Pooramiri; Davood Mansouri; Parisa Farnia; Mohammadreza Masjedi; Aliakbar Velayati
Journal:  Am J Ther       Date:  2011 Mar-Apr       Impact factor: 2.688

5.  High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho.

Authors:  H Satti; A Mafukidze; P L Jooste; M M McLaughlin; P E Farmer; K J Seung
Journal:  Int J Tuberc Lung Dis       Date:  2012-04       Impact factor: 2.373

6.  HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality.

Authors:  Neel R Gandhi; N Sarita Shah; Jason R Andrews; Venanzio Vella; Anthony P Moll; Michelle Scott; Darren Weissman; Claudio Marra; Umesh G Lalloo; Gerald H Friedland
Journal:  Am J Respir Crit Care Med       Date:  2009-10-15       Impact factor: 21.405

7.  Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.

Authors:  Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

8.  Psychiatric issues in the management of patients with multidrug-resistant tuberculosis.

Authors:  P Vega; A Sweetland; J Acha; H Castillo; D Guerra; M C Smith Fawzi; S Shin
Journal:  Int J Tuberc Lung Dis       Date:  2004-06       Impact factor: 2.373

9.  Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa.

Authors:  Kwonjune J Seung; David B Omatayo; Salmaan Keshavjee; Jennifer J Furin; Paul E Farmer; Hind Satti
Journal:  PLoS One       Date:  2009-09-25       Impact factor: 3.240

10.  Multidrug-resistant tuberculosis.

Authors:  Ellen M Zager; Ruth McNerney
Journal:  BMC Infect Dis       Date:  2008-01-25       Impact factor: 3.090

View more
  13 in total

1.  Discordance between patient and clinician reports of adverse reactions to MDR-TB treatment.

Authors:  A M Kelly; B Smith; Z Luo; B Given; T Wehrwein; I Master; J E Farley
Journal:  Int J Tuberc Lung Dis       Date:  2016-04       Impact factor: 2.373

2.  Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa.

Authors:  James C M Brust; N Sarita Shah; Koleka Mlisana; Pravi Moodley; Salim Allana; Angela Campbell; Brent A Johnson; Iqbal Master; Thuli Mthiyane; Simlatha Lachman; Lee-Megan Larkan; Yuming Ning; Amyn Malik; Jonathan P Smith; Neel R Gandhi
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

Review 3.  Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis.

Authors:  Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren
Journal:  Lancet Respir Med       Date:  2014-03-24       Impact factor: 30.700

4.  Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV.

Authors:  M R O'Donnell; A Daftary; M Frick; Y Hirsch-Moverman; K R Amico; M Senthilingam; A Wolf; J Z Metcalfe; P Isaakidis; J L Davis; J R Zelnick; J C M Brust; N Naidu; M Garretson; D R Bangsberg; N Padayatchi; G Friedland
Journal:  Int J Tuberc Lung Dis       Date:  2016-04       Impact factor: 2.373

5.  Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa.

Authors:  Amrita Daftary; Nesri Padayatchi; Max O'Donnell
Journal:  Glob Public Health       Date:  2014-07-18

Review 6.  Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.

Authors:  H Hong; C Budhathoki; J E Farley
Journal:  Int J Tuberc Lung Dis       Date:  2018-06-01       Impact factor: 2.373

7.  Dilemma of managing asymptomatic children referred with 'culture-confirmed' drug-resistant tuberculosis.

Authors:  Marian Loveday; Babu Sunkari; Ben J Marais; Iqbal Master; James C M Brust
Journal:  Arch Dis Child       Date:  2016-04-04       Impact factor: 3.791

8.  The effect of human immunodeficiency virus infection on adverse events during treatment of drug-resistant tuberculosis: A systematic review and meta-analysis.

Authors:  Gilbert Lazarus; Kevin Tjoa; Anthony William Brian Iskandar; Melva Louisa; Evans L Sagwa; Nesri Padayatchi; Vivian Soetikno
Journal:  PLoS One       Date:  2021-03-04       Impact factor: 3.240

9.  The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.

Authors:  Jonathan P Smith; Neel R Gandhi; N Sarita Shah; Koleka Mlisana; Pravi Moodley; Brent A Johnson; Salim Allana; Angela Campbell; Kristin N Nelson; Iqbal Master; James C M Brust
Journal:  J Acquir Immune Defic Syndr       Date:  2020-01-01       Impact factor: 3.771

10.  High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India.

Authors:  Aristomo Andries; Petros Isaakidis; Mrinalini Das; Samsuddin Khan; Roma Paryani; Chitranjan Desai; Alpa Dalal; Homa Mansoor; Reena Verma; Dolorosa Fernandes; Giovanni Sotgiu; Giovanni B Migliori; Peter Saranchuk
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.